Reviva Stock: Positive Results In Phase 3 But The Stock Is Back Where It Started (RVPH)


Going round in circles

RTimages/iStock via Getty Images

When I last wrote about Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) in September, I rated it a buy ahead of upcoming results from the phase 3 RECOVER study of its antipsychotic brilaroxazine in schizophrenia. This article takes





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *